Complications from an unknown gastric diffuse large B-cell lymphoma: A case report

William Sergi, S Ricci, I M Barbieri, S Bonilauri, G Frazzetta

ABSTRACT

Introduction: Non-epithelial gastric primary tumors are non-common pathological entities, known for its indolent clinical course and excellent survival compared with other kinds of malignant tumor. Obstruction, perforation, or bleeding are complications we rarely observed but they can be the first presentation of these disease. The treatment strategy is still controversial and in a few cases surgery has a determinant role.

Case Report: An 80-year-old man, with background of portal hypertension, came to emergency department with symptoms and signs of upper gastrointestinal (GI) perforation. Gastric resection was performed. The patient recovered well and was preparing for oncological therapy.

Conclusion: In this report we evidence particular clinical features and challenges in diagnosis and treatment strategies of primary gastric lymphomas, according with literature review.

Keywords: Gastric tumors, Lymphoma, MALT, Non-Hodgkin

INTRODUCTION

Mucosa-associated lymphoid tissues (MALTs) are characterized by an indolent clinical course and excellent survival compared with the other malignant tumor [1]. The clinical features of gastric MALT lymphoma are non-specific. It usually manifests as abdominal pain, vomiting, weight loss, etc., which can also be observed in gastric ulcer and any other tumor. Rarely we can observe complications (obstruction, perforation, or bleeding) like first appear once. Herein, we report a case of gastric diffuse large B-cell lymphoma, which presented itself with gastric perforation.

CASE REPORT

In January 2020, an 80-year-old man recurred to the Emergency Department with symptoms of upper gastrointestinal perforation. His background included left colon carcinoma (surgically removed 12 years ago and then treated with chemotherapy), Gilbert' syndrome, portal hypertension with known splenomegaly, thrombocytopenia, esophageal varices (treated with multiple endoscopic procedures) and mesenteric thrombosis (in treatment with anticoagulant).

Routine biochemistry shows a slight increase of leucocytes and C-reactive protein. Computed tomography (CT) scan revealed pneumoperitoneum with liquid layer in abdominal upper quadrants and a stomach with thickened walls (Figure 1).

In suspicion of perforated peptic ulcer, the patient underwent emergent explorative laparoscopy: the surgeons found a purulent peritonitis in the upper quadrants and, on the anterior wall of the stomach, a circular area, greater than 2.5 cm, with thickened walls, surmounted by a ulcerative crater with irregular and friable margins. Because of the failure of multiple attempts of laparoscopic suture, the surgeons decided...
for midline laparotomy: also in this case the direct suture was not sure, then they chose to partial gastrectomy and reconstruction with transmesocolic Roux-en-Y loop, wrapping mechanical T-L gastro-digjunal anastomosis and L-L jejunal-jejunal anastomosis (Figure 2).

At the end of the procedure, the patient was transferred to Intensive Care Unit. He received endovenous parenteral nutrition for eight days after the operation and was sent back to common ward on the sixth day. In fifth day he was on a liquid diet and in sixth one a diet for gastrectomized patients was introduced.

The tumor was located in the anterior wall of the stomach body toward the greater curvature (Figure 2). Histopathologic examination of the specimen revealed a diffuse growth pattern of large lymphocytes with an irregular nuclear profile, a high nuclear-cytoplasm ratio and evident immunophenotype B-nucleoli.

Immunohistochemical analysis revealed positivity for CD20, CD10, and Bcl6, whereas negative markers were MUM1/IRF4, Bcl2, CD30, cyclinD1, HHV8, and EBV-RNA (EBER).

Following negativity for c-MYC rearrangement (tested with FISH assay) the diagnosis was that of High grade mature B-cell lymphoma, compatible with “diffuse large B-cell lymphoma” (DLBCL) (Figures 3 and 4).

In light of the above, during the hospitalization the patient was evaluated by a hematologist: the specialist suggested the patient underwent chest CT-scan, positron emission tomography (PET)-whole body with F18-FDG, echocardiogram, and bone marrow biopsy, all negatives for systemic disease.

The patient had a good postoperative recovery and there was no complications; he was successfully discharged in 23rd day. He is regularly followed up at a postoperative clinic and is doing well; the multidisciplinary group proposed him 6 cycles of chemotherapy with R-MINI-COMP.

**DISCUSSION**

The GI tract is the predominant site of extranodal non-Hodgkin lymphomas (NHLs). Primary NHLs of the GI tract are rare, accounting for 1–4% of malignancies arising in the stomach, small intestine or colon. In contrast, secondary GI involvement is relatively common (10% of patients with limited stage NHL at the time of diagnosis, and >60% of those dying from advanced NHL): the following sites of involvement include...
stomach (68–75%), small bowel (including duodenum: 9%), ileo-cecal region (7%), rectum (2%), diffuse colonic involvement (1%), more than one GI site (6–13%) [2–5].

Primary gastric lymphoma (PGL) accounts for 3% of gastric neoplasms and 10% of lymphomas [6].

It mainly strikes adults (with a median age of 66 years at diagnosis) in all races, equally among men and women (gender disparities are seen by site); the exact incidence is unknown because most epidemiologic data come from developed countries [7].

The frequent histological subtypes of PGL (greater than 90%) are [8–11]:

- Marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT), that are low-grade lesions. It arises from post-germinal center memory B-cells with the capacity to differentiate into marginal zone cells and plasma cells. It can result from several epithelial tissues (the stomach above all): while it has a tendency to remain localized to the tissue of origin for long periods of time, it frequently recurs locally and has potential for systematic spread and transformation to an aggressive B-cell lymphoma.

- Diffuse large B-cell lymphoma (DLBCL) is high grade and more common than the first one.

Diffuse large B-cell lymphoma can arise de novo in the stomach or whether it transforms from low-grade MALT lymphomas [12, 13]. Diffuse large B-cell lymphoma is cyogenetically, biologically and clinically different tumors; it’s often called “high grade lymphoma” because:

- It is more aggressive clinically with rapid growth.

- It has large clusters or sheets of large B-cells (centroblast- or immunoblast-like cells) in mucosa associated lymphoid tissue, and it means a worse prognosis [14].

- Neither trisomy 3 or t(11;18)(q21;q21) is common in primary large cell lymphomas of the gastrointestinal tract [15, 16].

Diffuse large B-cell lymphoma must be distinguished from other B-cell neoplasms that may involve extranodal sites, like nodal and splenic marginal zone lymphoma or MALT lymphomas; sometimes they take a plasmacytic differentiation, then they go to differential diagnoses with other type of NHLs, such as lymphoplasmacytic lymphoma, follicular lymphoma, monocytoid B-cell lymphoma, and extraginous plasmacytoma [17].

### Diagnosis

Patients typically present with non-specific symptoms, seen in other common gastric diseases, such as peptic ulcer disease or adenocarcinoma. The most common presenting symptoms include epigastric pain or discomfort (78–93%), anorexia (47%), weight loss (frequently due to local compromise of GI structures: 25%), nausea and/or vomiting (18%), occult gastrointestinal bleeding (19%), early satiety [18–21].

Systemic B symptoms (fever, night sweats) are seen in 12% of patients; hematemesis and melena are uncommon. The duration of symptoms preceding the diagnosis is quite variable, ranging from a few days to six years.

The physical examination is often normal, but may reveal a palpable mass and/or peripheral lymphadenopathy when the disease is advanced. Laboratory studies also tend to be normal at presentation; anemia or an elevated erythrocyte sedimentation rate may be present in a few cases [19–21].

Radiology is also vague in diagnosing PGLs, showing a polyoid lesion or homogeneous concentric gastric wall thickening in CT scan, generally without a single interpretation. Magnetic resonance imaging (MRI) can help to define size and location of the lesion and its relationships with surrounding organizations [22]; PET-CT can find out the position of hypermetabolism, which can identify probability of malignancy.

The diagnosis of gastric lymphoma is usually established during upper endoscopy with biopsy. The endoscopic appearance of gastric PGL varies (mucosal erythema, a mass or polyoid lesion with or without ulceration, benign-appearing gastric ulcer, nodularity, thickened cerebriform gastric folds), than only biopsy have practical significances of diagnosis [23, 24].

An endoscopic ultrasound should determine the depth of invasion and the presence of perigastric nodes. The pattern seen on endoscopic ultrasound (EUS) may correlate with the type of lymphoma that is present: mass-forming lesions were typical of diffuse large B-cell lymphoma [24]. Endoscopic ultrasound alone has suboptimal accuracy in distinguishing benign from malignant lymph nodes. When combined with endoscopic biopsy, however, overall accuracy approaches 90% (versus 66% for EUS alone). Even higher accuracy rates may be achievable if flow cytometry is performed. Thus, caution is warranted in the interpretation of findings using EUS or CT alone [24–28].

Laparotomy and laparoscopy are typically reserved for patients with complications such as obstruction or perforation, like the case herein reported.

### Treatment

As a matter of fact, surgery is restricted to the treatment of complications such as bleeding, perforation or obstruction due to the tumor, and today it is not the first treatment, with its mortality rate reaching up to

---

Sergi et al. 3
8% [29]. Chemotherapy has surpassed surgery in terms of benefits and complications, and R-CHOP has been traditionally used as the frontline treatment in patients with localized gastric DLBCL [30]. The PET-CT should be done at the end of therapy, and if the patient has progressive disease, the consideration for second-line treatment (salvage chemotherapy) for DLBCL with a regimen, such as rituximab, ifosfamide, carboplatin, and etoposide or Gemcitabine, dexamethasone, and cisplatin and rituximab, followed by autologous stem cell transplantation should be considered [31].

CONCLUSION

Our case report evidences particular clinical features, challenge in diagnosis, and treatment strategies of primary gastric lymphomas. According to literature review, these diseases require specified medical management. Surgery is a therapeutic option in emergency setting when patients have had a complication.

REFERENCES

1. Freedman AS, Aster JC, Lister A, Connor RF. Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT). UpToDate 2019.
2. Papaxoinis G, Papageorgiou S, Rontogianni D, et al. Primary gastrointestinal non-Hodgkin's lymphoma: A clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma 2006;47(10):2140–6.
3. Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): A model for mature B-cell neoplasms. Blood 2005;105(6):2274–80.
4. Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001;19(18):3861–73.
5. Wang T, Gui W, Shen Q. Primary gastrointestinal non-Hodgkin's lymphoma: Clinicopathological and prognostic analysis. Med Oncol 2010;27(3):661–6.
6. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972;29(1):252–60.
7. Perry AM, Diebold J, Nathwani BN, et al. Non-Hodgkin lymphoma in the developing world: Review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project. Haematologica 2016;101(10):1244–50.
8. Zullo A, Hassan C, Ridola L, Repici A, Manta R, Andriani A. Gastric MALT lymphoma: Old and new insights. Ann Gastroenterol 2014;27(1):27–33.
9. Sagaert X, De Wolf-Peeters C, Noels H, Baens M. The pathogenesis of MALT lymphomas: Where do we stand? Leukemia 2007;21(3):389–96.
10. Yeh KH, Kuo SH, Chen LT, et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 2005;106(3):1037–41.
11. Wlodarska I, Veyt E, De Paepe P, et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations. Leukemia 2005;19(8):1299–305.
12. Raderer M, Kiesewetter B, Ferreri A. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). CA Cancer J Clin 2016;66(2):153–71.
13. Foster LH, Portell CA. The role of infectious agents, antibiotics, and antiviral therapy in the treatment of extranodal marginal zone lymphoma and other low-grade lymphomas. Curr Treat Options Oncol 2015;16(6):28.
14. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: Factors relevant to prognosis. Gastroenterology 1992;102(5):1628.
15. Ott G, Katzenberger T, Greiner A, et al. The t(11;18) (q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin’s lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res 1997;57(18):3944–8.
16. Barth TF, Döhner H, Werner CA, et al. Characteristic pattern of chromosomal gains and losses in primary large B-cell lymphomas of the gastrointestinal tract. Blood 1998;91(1):4321–30.
17. Krisnamoorthy N, Saidi MM, Madarwin M, Deodhar K, Mohandas KM. A rare case of primary gastric plasmacytoma: An unforeseen surprise. J Cancer Res Ther 2010;6(4):549–51.
18. Nakamura S, Matsumoto T. Treatment strategy for gastric mucosa-associated lymphoid tissue lymphoma. Gastroenterol Clin North Am 2015;44(5):649–60.
19. Cogliatti SB, Schmid U, Schumacher U, et al. Primary B-cell gastric lymphoma: A clinicopathological study of 145 patients. Gastroenterology 1991;101(5):1159–70.
20. Muller AF, Maloney A, Jenkins D, et al. Primary gastric lymphoma in clinical practice 1973–1992. Gut 1995;36(5):679–83.
21. Zhao ZH, Yang JF, Wang JD, Wei JG, Liu F, Wang BY. Imaging findings of primary gastric lymphoma in clinical practice 1973–1992. Gut 1995;36(5):679–83.
22. Fork FT, Haglund U, Höögström H, Wehlin L. Primary gastric lymphoma versus oral cancer. An endoscopic and radiographic study of differential diagnostic possibilities. Endoscopy 1985;17(1):5–7.
23. Caletti G, Ferrari A, Broecher E, Barbara L. Accuracy of endoscopic ultrasonography in the diagnosis and staging of gastric cancer and lymphoma. Surgery 1993;113(1):14–27.
24. Suekane H, Iida M, Yao T, Matsumoto T, Masuda Y, Fujishima M. Endoscopic ultrasonography in primary gastric lymphoma: Correlation with endoscopic and histologic findings. Gastrointest Endosc 1993;39(2):139–45.
25. Fischbach W, Goebeler-Kolve ME, Greiner A. Diagnostic accuracy of EUS in the local staging of...
primary gastric lymphoma: Results of a prospective, multicenter study comparing EUS with histopathologic stage. Gastrointest Endosc 2002;56(5):696–700.

26. Harada N, Wiersema M, Wiersema L. Endosonography guided fine needle aspiration biopsy (EUS FNA) in the evaluation of lymphadenopathy: Staging accuracy of EUS FNA versus EUS alone. Gastrointest Endosc 1997;45(2):A831.

27. Wiersema MJ, Gatzimos K, Nisi R, Wiersema LM. Staging of non-Hodgkin’s gastric lymphoma with endosonography-guided fine-needle aspiration biopsy and flow cytometry. Gastrointest Endosc 1996;44(6):734–6.

28. Roukos DH, Hottinger C, Encke A, Baltagiannis G, Casiomis D. Primary gastric lymphomas: A clinicopathologic study with literature review. Surg Oncol 1994;3(2):115–25.

29. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346(4):235–42.

30. Van Den Neste E, Schmitz N, Mounier N, et al. Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: An analysis of patients included in the CORAL study. Bone Marrow Transplant 2017;52(2):216–21.

*********

Author Contributions

William Sergi – Conception of the work, Design of the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

S Ricci – Acquisition of data, Analysis of data, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

I M Barbieri – Analysis of data, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

G Frazzetta – Interpretation of data, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Guarantor of Submission

The corresponding author is the guarantor of submission.

Source of Support

None.

Consent Statement

Written informed consent was obtained from the patient for publication of this article.

Conflict of Interest

Authors declare no conflict of interest.

Data Availability

All relevant data are within the paper and its Supporting Information files.

Copyright

© 2021 William Sergi et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
Submit your manuscripts at
www.edoriumjournals.com